[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-valve-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-valve-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,74,103,129,167,203,240,272],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100518226","ctsn-embolic-protection-trial-100518226",false,"NCT06027788","CTSN Embolic Protection Trial","Embolic Protection in Patients Undergoing High-Risk Valve Surgery","EMPRO","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Planned de novo or redo:\n\n  * Surgical aortic valve replacement SAVR ± ascending aortic repair (if circulatory arrest is not required) ± CABG\n  * Mitral valve replacement (MVR) ± CABG\n  * Mitral Valve Repair + CABG,\n  * Double\u002FTriple valve surgery ± CABG; Ross procedure These procedures can be done via a full or minimal-access sternotomy (using central aortic perfusion cannulae) with legally marketed valve(s), and can be done in combination with an left atrial appendage (LAA) closure\u002Fexcision or partial\u002Fcomplete Maze procedure.\n  * Valve sparing aortic root replacement (David procedure)\n  * Valve sparing aortic root replacement (David procedure)\n* No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤2 within 30 days prior to randomization\n* Ability to provide informed consent and comply with the protocol\n\nExclusion Criteria:\n\n* History of clinical stroke within 3 months prior to randomization\n* Cerebral and or aortic arch arteriography or interventions within 3 days of the planned procedure\n* Coronary catheterization within 3 days of index procedure, and the required repeat NIHSS score post-catheterization is worse than the screening\u002Fbaseline NIHSS score conducted prior to the catheterization\n* Active endocarditis at time of randomization with vegetation criteria\n* Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization\n* Participation in an interventional (drug or device) trial\n* Isolated mitral valve repair, isolated tricuspid valve repair or combined mitral valve repair and tricuspid valve repair\n* Anticipated requirement for prolonged mechanical ventilation greater than 48 hours after surgery in the opinion of the investigator\n* Planned concomitant carotid endarterectomy during index surgical procedure","ALL","60 Years",{"count":20,"type":21},842,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.",[27,28,29,30,31],"Delirium","Ischemic Stroke","Acute Kidney Injury","Heart Valve Disease","Coronary Artery Disease",[33,34,35],"Embolic Protection","Cardiac Surgery","CardioGard","RECRUITING","2026-05-26",{"date":39,"type":40},"2026-05-29","ACTUAL",{"date":42,"type":40},"2023-09-18",{"date":44,"type":21},"2027-04-01",{"name":46,"class":47},"Icahn School of Medicine at Mount Sinai","OTHER",28,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100638675","serratus-posterior-superior-intercostal-plane-block-in-minimally-invasive-cardiac-surgery-100638675","NCT07588230","Serratus Posterior Superior Intercostal Plane Block in Minimally Invasive Cardiac Surgery","Preoperative Serratus Posterior Superior Intercostal Plane Block for Analgesia and Opioid Sparing in Patients Undergoing Minimally Invasive Cardiac Valve Surgery Via Mini-Thoracotomy: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Adult patients aged 18-75 years\n* ASA physical status I-III\n* Scheduled for elective minimally invasive cardiac valve surgery via mini-thoracotomy\n* Able to understand and use the Numeric Rating Scale (NRS)\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Age \\>75 years\n* Known allergy or hypersensitivity to local anesthetics (e.g., bupivacaine)\n* Coagulopathy or ongoing anticoagulant therapy that cannot be discontinued\n* Infection at the planned block site\n* Chronic opioid use or chronic pain conditions\n* Severe pulmonary disease affecting respiratory assessment\n* Neurological or psychiatric disorders interfering with pain assessment\n* Emergency surgery\n* Pregnancy or breastfeeding\n* Refusal to participate","18 Years","75 Years",{"count":59,"type":21},90,[24],"This randomized, double-blind, placebo-controlled study aims to evaluate the effect of the serratus posterior superior intercostal plane (SPSIP) block on postoperative pain and opioid consumption in patients undergoing minimally invasive cardiac valve surgery via mini-thoracotomy.",[30,63],"Postoperative Pain",[34,63],"2026-05-16",{"date":67,"type":40},"2026-05-19",{"date":65,"type":40},{"date":70,"type":21},"2026-10-26",{"name":72,"class":47},"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100632283","the-study-tests-if-preoperative-dental-screening-is-superior-to-no-preoperative-dental-screening-in-improving-the-outcome-of-patients-undergoing-surgical-cardiac-valve-replacement-or-transcatheter-cardiac-valve-implantation-100632283","NCT07511673","The Study Tests if Preoperative Dental Screening is Superior to no Preoperative Dental Screening in Improving the Outcome of Patients Undergoing Surgical Cardiac Valve Replacement or Transcatheter Cardiac Valve Implantation.","SMILE: A Randomized Trial of Preoperative Dental Screening for the Prevention of Endocarditis, Reoperation or Death in Patients Undergoing Surgical or Transcatheter Cardiac Valve Intervention.","SMILE","Inclusion Criteria:\n\n* Age ≥18 years\n* Accepted for cardiac valve intervention\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Previous or ongoing infective endocarditis\n* Urgent surgery\n* Pain from loose tooth\u002Fteeth\n* Immunosuppressive therapy (excluding corticosteroids)\n* Inability to provide informed consent\n* Expected loss to follow-up",{"count":83,"type":21},1300,[24],"This randomized, multicenter, open-label trial evaluates whether preoperative dental screening improves outcomes in patients undergoing surgical or transcatheter cardiac valve intervention. Participants are randomized 1:1 to preoperative dental screening or no screening. The primary outcome is time to first occurrence of all-cause death, redo-intervention of the index valve, or definite infective endocarditis within 2 years. The study uses registry-based follow-up to ensure complete outcome ascertainment.",[87,30],"Infective Endocarditis (IE)",[89,90,91,92,93],"Dental screening","valve intervention","endocarditis","TAVI","valve surgery","2026-05-15",{"date":67,"type":40},{"date":97,"type":40},"2026-05-06",{"date":99,"type":21},"2036-12-01",{"name":101,"class":47},"Region Skane",5,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":128},"100560770","the-tricure-eu-pivotal-study-100560770","NCT06581471","The TRICURE EU Pivotal Study","The TRICURE EU PIVOTAL TRiCares Topaz Transcatheter TRICUspid Heart Valve REplacement System EUropean PIVOTAL Study","TRICURE EU","Inclusion Criteria:\n\n* Adult patients\n* Tricuspid regurgitation grade 3 (severe) on a scale of 0 (none) to 5 (torrential)\n* Institutional Heart Team evaluates patient as being at increased operative risk\n\nExclusion Criteria:\n\n* Patient in need of emergent intervention\n* Patient who is hemodynamically unstable\n* Anatomical contraindications for implantation with study device\n* Patient who is currently participating in another clinical investigation where the primary endpoint was not reached yet",{"count":112,"type":21},80,[24],"Prospective, multi-center study to assess safety and performance of the TRiCares Topaz Tricuspid Valve Replacement System",[116,30,117],"Tricuspid Valve Regurgitation","Cardiovascular Diseases","2026-04-10",{"date":120,"type":40},"2026-04-15",{"date":122,"type":40},"2024-08-29",{"date":124,"type":21},"2030-12-30",{"name":126,"class":127},"TRiCares","INDUSTRY",8,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":147,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":73},"100633038","llm-based-intelligent-health-management-assistant-in-life-cycle-health-management-of-cardiac-surgery-patients-100633038","NCT07521488","LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients","Application of Large Language Model-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Patients After Cardiac Surgery: A Prospective Randomized Controlled Study","cFT-LLM","Inclusion Criteria:\n\n1. Aged 18 years or older, any sex\n2. Underwent cardiac surgery at the Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, including but not limited to: coronary artery bypass grafting (CABG), heart valve replacement or repair (aortic valve, mitral valve, or tricuspid valve surgery), great vessel surgery (aortic dissection or aortic aneurysm repair), congenital heart disease correction, or cardiac assist device implantation\n3. Clinically stable after surgery and eligible for hospital discharge\n4. Has access to a smartphone and is capable of independently operating a mobile application, or has a family member available to assist with operation\n5. Voluntarily participates in the study, understands and signs the informed consent form, and is able to comply with the study protocol requirements\n\nExclusion Criteria:\n\n1. Postoperative intensive care unit (ICU) stay exceeding 30 days, or presence of severe uncontrolled postoperative complications such as persistent infection or multi-organ failure\n2. Life expectancy less than 12 months due to advanced malignancy or end-stage organ failure\n3. Severe cognitive impairment, psychiatric disorder, or inability to understand and use a mobile application without available caregiver assistance\n4. Heart transplant recipient\n5. Currently participating in another interventional clinical study\n6. Anticipated inability to complete 12-month follow-up",{"count":138,"type":21},500,[24],"This is a single-center, prospective, randomized, open-label, parallel-controlled clinical study to evaluate the effectiveness of a large language model (LLM)-based intelligent health management assistant in the life-cycle health management of patients after cardiac surgery. A total of 500 adult patients who undergo cardiac surgery (including coronary artery bypass grafting, heart valve surgery, great vessel surgery, congenital heart disease correction, and other cardiac procedures) at Beijing Anzhen Hospital will be randomly assigned in a 1:1 ratio to an intervention group or a control group, stratified by age (\\\u003C65 vs ≥65 years) and surgery type. The intervention group will use the LLM-based mobile health management application in addition to standard postoperative care, while the control group will receive standard postoperative care alone. The application integrates multimodal clinical data into a personalized health profile and provides surgery-type-specific postoperative management recommendations, medication adherence reminders, complication early warning, and cardiac rehabilitation guidance. The primary outcome is the composite endpoint of major adverse cardiac and cerebrovascular events (MACCE), defined as all-cause death, non-fatal myocardial infarction, non-fatal stroke, or unplanned cardiovascular reoperation\u002Freintervention, within 12 months after randomization. Secondary outcomes include health-related quality of life (EQ-5D-5L), cardiovascular rehospitalization rate, medication adherence (MMAS-8), postoperative complication rate, and cardiac rehabilitation achievement rate. Follow-up visits are scheduled at 1, 3, 6, 9, and 12 months post-randomization.",[142,30,143,144,145,146],"Coronary Artery Bypass Grafting","Aortic Aneurysm","Aortic Dissection","Congenital Heart Disease","Cardiac Surgical Procedures",[148,149,34,150,151,152,153,154,155,156],"Large Language Model","Artificial Intelligence","Postoperative Health Management","Digital Health","Medication Adherence","Cardiac Rehabilitation","MACCE","Mobile Health Application","Personalized Health Management","NOT_YET_RECRUITING","2026-04-08",{"date":160,"type":40},"2026-04-13",{"date":162,"type":21},"2026-05-01",{"date":164,"type":21},"2027-12-31",{"name":166,"class":47},"Beijing Anzhen Hospital",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":174,"minAge":56,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":73},"100618380","warfarin-effects-on-male-fertility-after-cardiac-surgery-100618380","NCT07330869","Warfarin Effects on Male Fertility After Cardiac Surgery","Effects of Warfarin Therapy on Semen Quality, DNA Integrity, Hormonal Profile and Molecular Alterations in Male Patients Undergoing Cardiac Surgery: A Prospective Comparative Pilot Study","Inclusion Criteria:\n\n* Male sex, age between 18 and 50 years;\n* Scheduled for elective cardiac surgery (valve replacement, valve repair, or other cardiac procedures) with or without indication to Warfarin therapy;\n* Ability and willingness to provide semen samples at scheduled timepoints;\n* No previous diagnosis of male infertility documented in medical records;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Known severe testicular pathology (for example, untreated high-grade varicocele, history of cryptorchidism, orchiectomy, testicular tumors);\n* Prior chemotherapy or pelvic radiotherapy;\n* Current or recent use of anabolic steroids or other drugs known to strongly impair spermatogenesis;\n* Known endocrine disorders affecting spermatogenesis (for example, untreated hypogonadism, hyperprolactinaemia, severe thyroid disease);\n* Active genitourinary infection at the time of evaluation;\n* Life expectancy less than 12 months or clinical conditions preventing adherence to follow-up.","MALE","50 Years",{"count":59,"type":21},"OBSERVATIONAL","Young male patients undergoing cardiac surgery may require oral anticoagulation with warfarin either lifelong, such as after mechanical valve replacement, or for a limited postoperative period, for example following valve repair or bioprosthetic valve implantation. Although the teratogenic effects of warfarin during pregnancy are well established, prospective clinical data on the potential impact of warfarin therapy on male reproductive health are scarce. This gap is particularly relevant for patients of reproductive age who may have a present or future desire for fatherhood.\n\nWarfarin acts as a vitamin K antagonist by inhibiting the vitamin K epoxide reductase complex, thereby reducing the availability of functional vitamin K. Beyond its role in coagulation, vitamin K is increasingly recognized as an important regulator of spermatogenesis, mitochondrial function, oxidative balance, and steroid hormone synthesis. Experimental and translational evidence suggests that disruption of vitamin K-dependent pathways may impair sperm quality, DNA integrity, mitochondrial bioenergetics, and reproductive hormone homeostasis. In addition, warfarin exposure has been associated with increased oxidative stress and inflammatory responses, both of which are known contributors to male infertility.\n\nDespite these biologically plausible mechanisms, no prospective observational studies have systematically evaluated semen parameters, sperm DNA fragmentation, hormonal profiles, inflammatory markers, and advanced molecular sperm alterations in men exposed to warfarin after cardiac surgery. Consequently, structured andrological assessment is rarely incorporated into routine preoperative counseling or postoperative follow-up in this population.\n\nThis prospective pilot observational study aims to investigate the association between warfarin therapy and male reproductive health in patients undergoing elective cardiac surgery. Male patients aged 18 to 50 years will be enrolled and observed in three cohorts based on clinical indication for anticoagulation: (1) long-term warfarin therapy following mechanical valve replacement; (2) short-term warfarin therapy (approximately three months) after selected cardiac procedures; and (3) a control cohort undergoing cardiac surgery without an indication for long-term oral anticoagulation beyond standard perioperative prophylaxis.\n\nParticipants will undergo comprehensive andrological assessments at baseline and during follow-up up to 12 months after surgery. Evaluations will include semen analysis according to World Health Organization guidelines, assessment of sperm DNA fragmentation, reproductive hormonal profiles, and seminal inflammatory markers. Exploratory analyses will assess mitochondrial function, oxidative stress, and molecular alterations in spermatozoa. Detailed warfarin exposure data, including dose, cumulative exposure, international normalized ratio values, and time in therapeutic range, will be collected to explore potential exposure-response relationships.\n\nAs a pilot study, the primary aims are to assess feasibility and generate preliminary clinical evidence to inform future larger studies. The findings may contribute to improved clinical counseling, fertility preservation strategies, and integration of reproductive health considerations into the multidisciplinary management of young male cardiac surgery patients.",[180,30],"Male Infertility",[182,183,184,185,186,187,188,189,190,191,192,193],"warfarin","male infertility","Semen quality","Sperm DNA fragmentation","Mitochondrial function","Inflammation","Mechanical heart valve","Cardiac surgery","Oral anticoagulation","Vitamin K antagonists","Reproductive hormones","anticoagulation","2025-12-29",{"date":196,"type":40},"2026-01-09",{"date":198,"type":21},"2026-02",{"date":200,"type":21},"2028-06",{"name":202,"class":47},"Città di Lecce Hospital, GVM Care & Research",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":213,"conditions":214,"keywords":227,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100613478","cohort-observing-mechanisms-progression-and-sequelae-of-valvular-heart-disease-100613478","NCT07267117","Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease","Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease (VALVE-COMPASS)","VALVE-COMPASS","Inclusion Criteria:\n\n* At least 18 years old;\n* Be willing and able to provide informed consent to participate in the study;\n* Patients with heart valve disease diagnosed by echocardiography who meet one of the following criteria:\n\n  1. Grade II or higher Aortic valve regurgitation: regurgitant jet width \\>3 mm, jet width \u002F LVOT diameter ≥25%, jet cross-sectional area\u002FLVOT cross-sectional area ≥5%, effective regurgitant orifice area (EROA) ≥0.1 cm², regurgitant volume per beat (R Vol)≥30 ml, or regurgitant fraction (RF) ≥30%.\n  2. Moderate or higher aortic valve stenosis: peak velocity ≥3.0 m\u002Fs, Mean gradient ≥20 mm Hg, aortic valve area ≤1.5 cm², Indexed aortic valve area ≤0.85 cm²\u002Fm², or velocity ratio ≤0.50.\n  3. Grade II or higher mitral valve regurgitation: regurgitant jet width ≥3 mm, regurgitant volume per beat ≥30 ml, regurgitant jet area\u002Fleft atrial area \\>30%, or effective regurgitant orifice area (EROA) ≥0.2 cm².\n  4. Moderate or higher valve stenosis: valve area (specific finding) ≤1.5 cm², or mean gradient (supportive finding) ≥10.0 mmHg.\n  5. Grade II or higher tricuspid valve regurgitation: regurgitant jet width ≥3 mm, proximal isovelocity surface area ≥6 mm, effective regurgitant orifice area (EROA) ≥0.2 cm², or regurgitant volume per beat ≥30 ml.\n  6. Significant tricuspid valve stenosis: mean pressure gradient ≥5.0 mmHg, inflow time-velocity integral \\>60 cm, T1\u002F2 ≥190 ms, or valve area ≤1.0 cm².\n  7. Grade II or higher pulmonary valve regurgitation: regurgitant jet width \\>3 mm, regurgitant volume per beat ≥30 ml, regurgitant fraction ≥30%, or effective regurgitant orifice area (EROA) ≥0.1 cm².\n  8. Moderate or higher Pulmonary valve stenosis: pulmonary valve transvalvular pressure gradient ≥40 mmHg, right ventricular systolic pressure ≥60 mmHg, or pulmonary valve opening \\\u003C1.5 cm².\n\nExclusion Criteria:\n\n* Patients who are unwilling to accept registration and follow-up;\n* Patients who cannot cooperate with information collection and follow-up due to mental illness or other conditions;\n* Patients whose life expectancy is less than 12 months due to non-cardiac diseases (such as cancer, liver disease, kidney disease, or end-stage lung disease).",{"count":212,"type":21},10000,"The objective of this study is to evaluate and predict the progression of moderate cardiac valve stenosis and regurgitation using clinical, biological, echocardiographic, computed tomography (CT), and magnetic resonance imaging (MRI) data. Additionally, the study aims to analyze the potential impact of device-based interventions, pharmacological therapy, and lifestyle modifications on disease progression.",[30,215,216,217,218,219,220,116,221,222,223,224,225,226],"Mitral Valve (MV) Regurgitation","Mitral Valve Disease","Mitral Valve Stenosis","Aortic Valve Disease","Aortic Valve Stenosis","Tricuspid Valve Disease","Aortic Valve Regurgitation","Pulmonary Valve Disease","Transcatheter Valve Replacement","Transcatheter Aortic Valve Replacement (TAVR)","Transcatheter Pulmonary Valve Replacement (TPVR)","Transcatheter Edge-to-edge Repair",[228,229],"Heart Valve Disease Progression","Heart Valve disease sequelae","2025-11-25",{"date":232,"type":40},"2025-12-05",{"date":234,"type":40},"2025-06-01",{"date":236,"type":21},"2030-05-31",{"name":238,"class":47},"Second Affiliated Hospital, School of Medicine, Zhejiang University",15,{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":249,"conditions":250,"keywords":257,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":239},"100609357","enhanced-valves-interventions-and-safe-ai-generated-end-results-100609357","NCT07213531","Enhanced Valves Interventions and Safe AI Generated End Results","ENVISAGE","Inclusion Criteria:\n\nPatients who have reached the age of legal majority under local laws.\n\n* For TAVI group: All patients who have had TAVI with a third generation transcatheter heart valve (THV), with an available pre-procedural optimal quality CT scan as defined by an ECG- gating CT with:\n\n  1. five to ten image volumes at cardiac phases from 5% to 95% R-R\n  2. 0.625 mm slice thickness\n  3. 0.625 mm spacing between slices\n  4. 0.88 mm in-plane pixel spacing\n* For TMVI group: Patients who have had a TMVI with a dedicated device and screen failures, with an available optimal quality CT scan.\n* For TTVI group: Patients who have had a TTVI with a dedicated device and screen failures, with an available optimal quality CT scan.\n* For M-TEER: All patient who have had a M-TEER with 1) G4 or newer iteration of MitraClip or 2) G2 or newer iteration of Pascal, with available pre-procedural TEE videos images from one of two vendors: Phillips or GE, with clear identifiable views of the Mitral valve, frame per second equal or higher than 40 frames per second, acceptable 3D reconstructions.\n* For T-TEER: All patient who have had a T-TEER with G4 or newer iteration of TriClip or 2) G2 or newer iteration of Pascal, with available pre-procedural TEE videos images from one of two vendors: Phillips or GE, with clear identifiable views of the Tricuspid valve, frame per second equal or higher than 40 frames per second, acceptable transgastric image with acceptable 3D reconstructions.\n\nExclusion Criteria:\n\n* For TAVI group: Valve-in-valve procedures\n* For TMVI group: Valve-in-valve and valve-in-ring procedures\n* For TTVI: Valve-in-valve and valve-in-ring procedures\n* For M-TEER: G3 or older MitraClip, G1 Pascal\n* For T-TEER: G3 Triclip, G1 Pascal",{"count":248,"type":21},21000,"This non-interventional study aims to use artificial intelligence to improve the prediction of transcatheter heart valve interventions and optimize patient outcomes. It is based on the analysis of retrospective data from various specialized centers worldwide.",[30,92,251,252,253,254,255,256],"M-TEER","TTVI","TMVI","T-TEER","Mitraclip","TriClip",[258,259,260,251,254,92,253,261,262],"Medical imaging","CT","Artificial intelligence","valvulopathy","predictive algorithms","2025-10-01",{"date":265,"type":40},"2025-10-09",{"date":267,"type":40},"2024-05-01",{"date":269,"type":21},"2029-05",{"name":271,"class":47},"Montreal Heart Institute",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":73},"100182683","myocardial-protection-effect-of-simvastatin-undergoing-cardiac-surgery-100182683","NCT01653223","Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery","A Study of Simvastatin on Myocardial Protection and Cardiac Function Undergoing Cardiac Surgery With Cardiopulmonary Bypass","Inclusion Criteria:\n\n* More than 18-year-old,\n* Congenital heart disease(not complex),\n* Isolated heart valve disease,\n\nExclusion Criteria:\n\n* Coronary artery disease\n* Allergy for statins\n* Poor liver function,Hepatitis\n* Gestation women and Breast-feeding women",{"count":280,"type":21},369,[24],"Statins have been used to low cholesterol to prevent and treat coronary artery diseases. It was also reported that statins could protect endothelial function and cardiac function during coronary artery bypass graft. The investigators recent found simvastatin reduced myocardial injury during noncoronary artery cardiac surgery in single medical center. The investigators further investigate that whether simvastatin can protect myocardium during noncoronary artery cardiac surgery with cardiopulmonary bypass and improve cardiac function with long term use postoperatively in two medical centers.",[145,30],"2023-04-19",{"date":286,"type":40},"2023-04-21",{"date":288,"type":4},"2013-01",{"date":290,"type":21},"2026-12",{"name":292,"class":47},"Sun Yat-sen University"]